Skip to main content
Fig. 1 | BMC Health Services Research

Fig. 1

From: A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures

Fig. 1

Odds ratio (95 % CIs) of canagliflozin 100 mg vs. glimepiride and canagliflozin 300 mg vs. glimepiride in the proportion of patients achieving QMs at Week 52. Mean (SD) maximum dose of GLIM was 5.6 (2.3) mg. CANA, canagliflozin; GLIM, glimepiride; QMs, quality measures; SD, standard deviation; 95 % Cl, 95 % confidence interval

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us